These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 39207773

  • 1. Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
    Ruiz-Esteves KN, Shank KR, Deutsch AJ, Gunturi A, Chamorro-Pareja N, Colling CA, Zubiri L, Perlman K, Ouyang T, Villani AC, Florez JC, Gusev A, Reynolds KL, Miller KK, Udler MS, Sise ME, Rengarajan M.
    JAMA Oncol; 2024 Oct 01; 10(10):1409-1416. PubMed ID: 39207773
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG.
    Front Endocrinol (Lausanne); 2023 Oct 01; 14():1242830. PubMed ID: 38027216
    [Abstract] [Full Text] [Related]

  • 3. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR.
    J Immunother Cancer; 2021 Mar 01; 9(3):. PubMed ID: 33789879
    [Abstract] [Full Text] [Related]

  • 4. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N, Ithimakin S, Siripoon T, Sintawichai N, Sriuranpong V.
    BMC Cancer; 2021 Nov 25; 21(1):1275. PubMed ID: 34823493
    [Abstract] [Full Text] [Related]

  • 5. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA.
    Arthritis Rheumatol; 2022 Mar 25; 74(3):527-540. PubMed ID: 34397169
    [Abstract] [Full Text] [Related]

  • 6. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K.
    Diabetes Res Clin Pract; 2023 Aug 25; 202():110776. PubMed ID: 37311494
    [Abstract] [Full Text] [Related]

  • 7. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I, Madison C, Kohn A, Berry E, Kulkarni RP, Thompson RF.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2340695. PubMed ID: 37906189
    [Abstract] [Full Text] [Related]

  • 8. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J, Stoff R, Ramon-Gonen R, Ben-Betzalel G, Grynberg S, Frommer RS, Schachter J, Asher N, Taliansky A, Nikitin V, Dori A, Shelly S.
    Neurology; 2023 Dec 12; 101(24):e2472-e2482. PubMed ID: 37652699
    [Abstract] [Full Text] [Related]

  • 9. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M, Navani V.
    JAMA Netw Open; 2024 Jan 02; 7(1):e2352302. PubMed ID: 38236598
    [Abstract] [Full Text] [Related]

  • 10. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J.
    JAMA Oncol; 2020 Dec 01; 6(12):1952-1956. PubMed ID: 33119034
    [Abstract] [Full Text] [Related]

  • 11. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV, Pond GR, Abou Alaiwi S, Nassar AH, Flippot R, Curran C, Kilbridge KL, Wei XX, McGregor BA, Choueiri T, Harshman LC, Sonpavde G.
    J Immunother Cancer; 2020 Mar 01; 8(1):. PubMed ID: 32234849
    [Abstract] [Full Text] [Related]

  • 12. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y, Kim R, Yu T, Gayle JA, Wassel CL, Dreyfus J, Phatak H, George S.
    Oncologist; 2021 Nov 01; 26(11):e2002-e2012. PubMed ID: 34327774
    [Abstract] [Full Text] [Related]

  • 13. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM.
    J Clin Endocrinol Metab; 2021 Aug 18; 106(9):e3704-e3713. PubMed ID: 33878162
    [Abstract] [Full Text] [Related]

  • 14. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
    Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246400. PubMed ID: 36512357
    [Abstract] [Full Text] [Related]

  • 15. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V, Patwari A, Harb AJ.
    J Cancer Res Clin Oncol; 2021 Sep 01; 147(9):2789-2800. PubMed ID: 33774736
    [Abstract] [Full Text] [Related]

  • 16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS.
    Urol Oncol; 2021 Jul 01; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [Abstract] [Full Text] [Related]

  • 17. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer.
    Rong Y, Bentley JP, Bhattacharya K, Yang Y, Chang Y, Earl S, Ramachandran S.
    Cancer Med; 2024 Jan 01; 13(1):e6879. PubMed ID: 38164655
    [Abstract] [Full Text] [Related]

  • 18. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J.
    JAMA Oncol; 2020 Jun 01; 6(6):865-871. PubMed ID: 32297899
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.